Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jan 10;6:1. doi: 10.1186/s40164-016-0061-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 1 — Representative CT scan images of target lesions showing response to dabrafenib monotherapy and dabrafenib and trametinib combination. Patient started treatment and showed response at the first 3 monthly CT scan (b, f) in all target lesions compared to the baseline (a, e). At the second 3 monthly CT scan the pelvic mass showed increased size (panel c, indicated by straight red line) compared to baseline while pulmonary metastases showed maintained response (panel g, representative image). Introduction of trametinib halted further progression of the pelvic mass (panel d) and induced further regression of the pulmonary metastases (panel h) suggesting that MEK inhibition can synergize and revert resistance to BRAF targeting agents in endometrial cancer harboring BRAF V600F mutation